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Abstract: Acute renal ischemia/reperfusion (I/R) injury is a clinical condition that is challenging to
treat. Meldonium is an anti-ischemic agent that shifts energy production from fatty acid oxidation
to less oxygen-consuming glycolysis. Thus, in this study we investigated the effects of a four-week
meldonium pre-treatment (300 mg/kg b.m./day) on acute renal I/R in male rats (Wistar strain).
Our results showed that meldonium decreased animal body mass gain, food and water intake,
and carnitine, glucose, and lactic acid kidney content. In kidneys of animals subjected to I/R,
meldonium increased phosphorylation of mitogen-activated protein kinase p38 and protein kinase
B, and increased the expression of nuclear factor erythroid 2-related factor 2 and haeme oxygenase
1, causing manganese superoxide dismutase expression and activity to increase, as well as lipid
peroxidation, cooper-zinc superoxide dismutase, glutathione peroxidase, and glutathione reductase
activities to decrease. By decreasing the kidney Bax/Bcl2 expression ratio and kidney and serum
high mobility group box 1 protein content, meldonium reduced apoptotic and necrotic events in I/R,
as confirmed by kidney histology. Meldonium increased adrenal noradrenaline content and serum,
adrenal, hepatic, and renal ascorbic/dehydroascorbic acid ratio, which caused complex changes in
renal lipidomics. Taken together, our results have confirmed that meldonium pre-treatment protects
against I/R-induced oxidative stress and apoptosis/necrosis.
Keywords: ischemia/reperfusion; kidney; inflammation; oxidative stress; antioxidative defence;
noradrenaline; lipidomics; rats
1. Introduction
Acute renal ischemia/reperfusion (I/R) is a temporary restriction of kidney blood supply,
followed by blood flow restoration and re-oxygenation. As the main cause of acute kidney injury,
it may occur due to aortic dissection, surgery, infarction, sepsis, or organ transplantation [1]. Due to
mortality being as high as 50% and the lack of efficient pharmacotherapy, I/R is still a challenging
condition in clinical medicine [2,3]. Although the precise pathophysiology of renal I/R is unclear,
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multiple pathways are involved, such as reactive oxygen species (ROS) formation, inflammation,
apoptosis, necrosis, and signalling pathway disruption [4,5].
Meldonium is an anti-ischemic drug clinically used to treat myocardial and cerebral ischemia [6].
Meldonium inhibits gamma-butyrobetaine dioxygenase, the enzyme catalyzing the final step in the
carnitine biosynthesis, and the carnitine palmitoyltransferase-1, an inner mitochondria membrane
enzyme that catalyzes transfer of the acyl group from coenzyme-A to carnitine. As a result, long-chain
fatty acids transport from cytosol into mitochondria is reduced and redirected to peroxisomes [7].
In peroxisomes, long-chain fatty acids are metabolized to medium- and short-chain acyl carnitines for
further oxidation in mitochondria, which prevents the mitochondrial accumulation of toxic long-chain
intermediates [8]. In this way, meldonium decreases the risk of a long-chain fatty acid and metabolism
mediated mitochondrial injury, thus shifting energy production from fatty acids oxidation to less
oxygen-demanding glycolysis, which is more favorable under ischemic conditions.
To address this issue, the aim of the present experiment was to investigate the effects of four-week
meldonium pre-treatment with 300 mg/kg b.m./day of rats subjected to a well-established experimental
model of renal I/R, with ischemia lasting for 45 minutes, followed by 4 hours of reperfusion [9].
The changes in body mass, body mass gain, and food and water intake were measured in sham and I/R
operated animals, with or without meldonium pre-treatment. The kidney concentration of carnitine,
glucose, and lactic acid were measured, as general markers of meldonium metabolic action. The degree
of kidney apoptosis and necrosis was evaluated by measuring kidney Bax/Bcl-2 ratio [10], as well
as serum and kidney levels of high mobility group box 1 protein (HMGB1) [11] together with the
kidney histology analysis [12]. The kidney antioxidative defense was investigated by measuring
the tissue expression of the nuclear factor erythroid 2-related factor 2 (Nrf2), haeme oxygenase
1 (HO-1), manganese superoxide dismutase (MnSOD), phosphorylation ratio of protein kinase B
(pAkt/Akt), mitogen-activated protein kinase p38 (pp38/p38), cooper-zinc superoxide dismutase
(CuZnSOD) activity, catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR),
glutathione S-transferase (GST), free sulfhydryl group (SH) concentration, and lipid peroxidation
level (thiobarbituric acid reactive substances, TBARS) [13–15]. Since ascorbic acid is a well-known
effector of the antioxidative system [16], our experiments also included a determination of ascorbic
acid (AA) and dehydroascorbic acid (DHA) ratio (AA/DHA) in the rat serum, adrenal gland, liver,
and kidney as a measure of its activity. Moreover, the link between ascorbic acid and catecholamine
production in the adrenal glands is also well known [17,18]. Keeping that in mind, together with
the fact that performed surgical interventions represent the stress that engages the sympathoadrenal
system, we also determined the noradrenaline (NA) and adrenaline (AD) concentrations in adrenal
glands. The analysis of 13 fatty acids was performed to evaluate the effects of meldonium and I/R on
kidney lipidomics.
2. Results and Discussion
There is little literature on the effects of meldonium on body mass gain and food and water intake,
except for two studies. Porter et al. [7] showed that a 10-day meldonium supplementation did not alter
these parameters. Liepinsh et al. [19] showed that meldonium decreased body mass gain in Zucker
obese rats, but only in combination with metformin.
Our measurement of body mass and food and water intake were completed before the surgical
procedures (sham or IR), meaning that all detected changes were caused by meldonium and not by
surgical procedures. As can be seen from our results, meldonium decreased body mass gain (Figure 1B,E)
and food (Figure 1C,E) and water intake (Figure 1D,E) in sham and I/R operated animals in comparison
with their respecting controls. The skin pinch test we performed showed no animal dehydration and
the trend of body mass changes in all experimental groups was similar, as proven by the curves with
the similar slope running parallel to each other (Figure 1A). We assume that meldonium, by shifting
mitochondrial ATP synthesis from fatty acid oxidation to less oxygen-consuming glycolysis [8], leads
to a more efficient yield of energy and metabolic water [20,21], which thus reduces food and water
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intake. Bearing in mind that a high-fat diet induces obesity in rats [22], and that meldonium modulates
cellular energy production pathway [8], it may be concluded that meldonium has the ability to act as
an anti-obesity agent.
Figure 1. Time-course curves of: (A) weekly body mass (g); (B) body mass gain (g/100 g b.m./week);
(C) food intake (g/kg b.m./day); and (D) water intake (mL/kg b.m./day, E): the area under a curve
values (% of sham) of weekly body mass, body mass gain, and food intake and water intake.
Group categories abbreviations: S—sham operated rat group; S + M—sham operated + meldonium rat
group; I/R—ischemia/reperfusion rat group; I/R + M—ischemia/reperfusion + meldonium rat group.
Number of animals per experimental group: n = 8. The data are given as mean ± standard error.
Minimal significant level: p < 0.05. Significantly different: a in respect to S; b in respect to S + M; c in
respect to I/R group.
The evidence that meldonium actually shifts metabolism towards a better utilized glucose are
that there are changes in the kidney content of carnitine, glucose, and lactic acid (Table 1). While I/R
did not change kidney concentration of carnitine and glucose, it caused a 3.6-fold increase in lactate
concentration, which is in line with the literature that confirms hypoperfusion as the main source of
tissue lactate concentration increase [23,24]. In aerobic conditions, the end product of glycolysis is
pyruvate, which upon formation enters the Krebs cycle to avoid lactate production [25]. Under anaerobic
conditions, the end product of glycolysis is lactate, so any obstruction in tissue oxygen supply, as is
the case with I/R, leads to its tissue concentration increase [26]. The I/R-induced kidney lactate
concentration increase was reduced by meldonium for almost 60%; the same effect was present in
sham operated animals (26.6-fold decrease in comparison to untreated rats). It should be noted that
in sham and I/R operated animals, meldonium decreased carnitine and glucose tissue concentration
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(Table 1), which his consistent with the literature data that shows an increase in glucose uptake and
decrease in lactate concentration in mice hearts treated with meldonium [27]. In this sense, it can be
said that our results confirm that meldonium stimulates aerobic oxidation of glucose by the inhibition
of carnitine synthesis, as previously suggested by Asaka et al. [28].
Table 1. Kidney carnitine, glucose, and lactic acid concentration (µg/g wet tissue mass). Group categories
abbreviations: S—sham operated rat group; S + M—sham operated + meldonium rat group;
I/R—ischemia/reperfusion rat group; I/R + M—ischemia/reperfusion + meldonium rat group. Number
of animals per experimental group: n = 8. The data are given as mean ± standard error. Minimal
significant level: p < 0.05. Significantly different: a in respect to S; b in respect to S + M; c in respect to
I/R group.
Experiment Groups S S + M I/R I/R + M
Carnitine 486.39 ± 34.02 148.66 ± 7.79 a 471.49 ± 22.7 b 385.03 ± 13.43 abc
Glucose 4.16 ± 0.27 1.85 ± 0.15 a 3.88 ± 0.35 b 2.28 ± 0.20 ac
Lactic acid 319.34 ± 25.90 11.83 ± 0.99 a 1164.07 ± 150.65 ab 685.54 ± 60.56 abc
During I/R, depleted oxygen supply causes dysfunctionality of the ATPase-dependent ion
transport and intracellular ATP. Further, pH levels decrease, intracellular and mitochondrial calcium
levels increase, and there is a disturbance in numerous signaling pathways [29]. Upon reperfusion,
a restoration of normal oxygen level causes a rise in ROS generation, a release of cytokines
and chemokines from activated tissue-resident macrophages, and infiltration of pro-inflammatory
neutrophils into ischemic tissues [23]. All these changes lead to cell swelling and rupture, as well as
consequent necrotic or apoptotic cell death. Cell death assumes a central role in the etiology of kidney
pathologies after I/R [30]. Renal cells may die during ischemia itself, in which case early membrane
damage leads to activation of multiple degradative systems in an uncontrolled fashion, referred to as
necrotic. However, the reperfusion-induced increase in ROS generation contributes to abnormal signal
transduction, cellular dysfunction, and cell death by apoptosis [31]. Cellular mechanisms that result in
apoptosis represent a cascade of numerous amplifying steps, including activation of pro-apoptotic
Bax protein, a member of the Bcl2 protein family [32]. It has been suggested that a delicate interplay
between anti- and pro-apoptotic members of the Bcl2 family is necessary for the repair of the damaged
renal cells after an ischemic insult [33]. Moreover, it has been reported that the over expression of
anti-apoptotic Bcl2 can block both apoptosis and necrosis [32], as well as protect ischemic tissue against
I/R-induced oxidative stress [34].
To examine the effect of meldonium pre-treatment on the extent of apoptosis activation in the
kidney subjected to I/R, we measured the changes in the Bax/Bcl2 ratio. Our results showed that I/R
increased the Bax/Bcl2 ratio by 2.7-fold and that meldonium reduced this increase for 35% (Figure 2A).
This finding indicates that the acceleration of pro-apoptotic events during I/R—as well as its effective
reduction by meldonium—is partially similar to the work of Shen et al. [10], who showed that ischemic
preconditioning decreased the Bax/Bcl2 ratio and increased under I/R conditions.
Apoptotic and necrotic cell death occur simultaneously under I/R conditions. Cellular death due
to necrosis result in the loss of cell membrane integrity and uncontrolled release of damage-associated
molecular pattern molecules (DAMPs) into the extracellular space. HMGB1, which belongs to the
DAMPs family, diffuses out of stressed, damaged, or dying cells, which is why it serves as necrotic
marker [35]. Our results show that I/R and meldonium changed HMGB1 expression in a manner
similar to Bax/Bcl2. While I/R caused an increase in serum (22%) and kidney (30%) levels of HMGB1,
concurrent meldonium pre-treatment reduced them for 20% (Figure 3A). These findings proved that
meldonium protects renal cells against I/R-induced necrosis, confirming results of Wu et al. [12],
who showed that treating mice with anti-HMGB1 antibodies protects kidneys against I/R injury.
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Figure 2. Representative immunoblots of protein expression levels: (A) kidney Bax, Bcl-2, HMGB1,
and serum HMGB1; (B) kidney MnSOD and total and phosphorylated p38/Akt; and (C) kidney Nrf2
and HO-1. β actin was used as a loading control. Group categories abbreviations: S—sham operated
rat group; S + M—sham operated + meldonium rat group; I/R—ischemia/reperfusion rat group;
I/R + M—ischemia/reperfusion + meldonium rat group. Number of animals per experimental group: n
= 8. Data are given as mean ± standard error. Minimal significant level: p < 0.05. Significantly different:
a in respect to S; b in respect to S + M; c in respect to I/R group.
It is known that I/R elevates ROS generation and decreases antioxidant defense through
antioxidative enzyme gene downregulation. Studies have reported the loss of the MnSOD enzyme
activity following I/R, with the MnSOD inactivation prior to the onset of renal damage, which suggests
an upstream of oxidative damage to renal damage [36]. It has also been reported that upregulation of
mitogen-activated protein kinase p38 alleviates I/R-induced renal tissue injury by activating protein
kinase B [37] and inducing Bcl2 and MnSOD expressions [38,39]. As can be seen from our results,
while I/R decreased the kidney MnSOD activity, meldonium pre-treatment increased it in both sham
and I/R operated animals (Table 2). The changes in MnSOD activity were accompanied by appropriate
changes in MnSOD expression level, as well as in the pp38/p38 and pAkt/Akt ratios as a measure of
their activation (Figure 2B). In comparison to sham operated animals, I/R decreased MnSOD expression
level by 20% and pp38/p38 and pAkt/Akt ratios by 50% and 10%, respectively. On the contrary, in I/R
animals, meldonium increased kidney expression of MnSOD by 1.12-fold and phosphorylation of p38
and Akt by 3.7- and 1.3-fold, respectively. Similarly, in kidney of sham operated animals, meldonium
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increased MnSOD expression level by 1.51-fold and p38 and Akt phosphorylation by 2.3- and 1.2-fold,
as compared to S group rats. These results clearly indicate that I/R causes adverse changes in kidney
antioxidative defence, while meldonium improves it in both I/R and sham operated animals.
Figure 3. Kidney histology analysis. Group categories abbreviations: (A) sham operated
rat group; (B) sham operated + meldonium rat group; (C–E) ischemia/reperfusion rat group;
(F) ischemia/reperfusion + meldonium rat group. (A,B) normal histological structure of glomeruli and
tubules; (C) severe tubular necrosis with dilatation of the tubular structure; (D) tubular necrosis and cast
formation, just rare cells showed apoptotic changes with dense nucleus and no inflammation (arrows);
(E) the reduction or loss of brush border, dilatation of tubular lumina, necrosis of epithelial tubular
cells as observed by the loss of nuclei (notice the loss of nuclei in many tubular cells marked by arrows);
(F) moderate kidney damage, focal tubular necrosis, and moderate dilatation of the tubular structure.
We also investigated the protein expression of Nrf2, which has been shown to be the most
important inducible transcription factor that exerts protective effects against renal ischemic damage
by regulating the endogenous antioxidant system. Once activated in cytosol, Nrf2 trans-activates
antioxidant response elements, which further promote the CuZnSOD, GSH-Px, GST, CAT, and HO-1
expression increase [40]. Several lines of evidence indicate that induced expression of HO-1 attenuates
cellular damage and reduces apoptosis, while HO-1 inhibition aggravates it [41]. Our results showed
that I/R decreased kidney Nrf2 (16%) and HO-1 (31%) expression levels by 16% and 31%, respectively,
while concurrent meldonium pre-treatment increased them by 2.6-fold in the case of Nrf2, and 1.2-fold
in case of HO-1 (Figure 2C). These findings suggest a new role of the Nrf2 signaling pathway in a
meldonium protection against renal I/R injury.
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Table 2. Activities of kidney copper-zinc superoxide dismutase (CuZnSOD, U/g wet mass), manganese
superoxide dismutase (MnSOD, U/g wet mass), catalase (CAT, µmol H2O2/min/g wet mass), glutathione
peroxidase (GSH-Px, µmol NADPH/min/g wet mass), glutathione reductase (GR, nmol NADPH/min/g
wet mass), and glutathione S-transferase (GST, nmol GSH/min/g wet mass), as well as kidney
concentrations of sulfhydryl groups (SH, nmol/g tissue) and lipid peroxides (TBARS, nmol/g tissue).
Group categories abbreviations: S—sham operated rat group; S + M—sham operated + meldonium rat
group; I/R—ischemia/reperfusion rat group; I/R + M—ischemia/reperfusion + meldonium rat group.
Number of animals per experimental group: n = 8. The data are given as mean ± standard error.
Minimal significant level: p < 0.05. Significantly different: a in respect to S; b in respect to S + M; c in
respect to I/R group.
Experiment Groups S S + M I/R I/R + M
CuZnSOD 2183.12 ± 126.99 1531.98 ± 45.87 a 2072.75 ± 93.81 b 1231.84 ± 117.88 ac
MnSOD 305.22 ± 22.94 644.35 ± 43.23 a 250.98 ± 6.07 ab 367.60 ± 32.99 bc
CAT 15,323.99 ± 494.06 15,569.04 ± 440.31 12,832.91 ± 348.47 ab 12,543.406 ± 512.92 ab
GSH-Px 41.69 ± 2.22 43.27 ± 2.36 42.94 ± 3.034 24.80 ± 0.97 abc
GR 16,495.17 ± 493.63 16,495.17 ± 696.70 16,495.17 ± 898.39 13,216.03 ± 277.42 abc
GST 25,328.13 ± 727.06 25,496.88 ± 878.78 24,042.19 ± 837.08 25,667.19 ± 1002.05
SH 3955.56 ± 215.29 5240.88 ± 357.92 a 3182.59 ± 105.86 ab 4496.62 ± 559.32 c
TBARS 1.24 ± 0.04 1.23 ± 0.03 1.44 ± 0.03 ab 1.26 ± 0.04 c
Unexpectedly, changes in Nrf2 expression were not accompanied by appropriate changes in the
activity of Nrf-2 associated antioxidant enzymes. As can be seen from Table 2, I/R did not change
CuZnSOD, GSH-Px, GR, and GST activities in comparison to sham operated animals. At the same
time, meldonium reduced CuZnSOD activity in rat kidneys from both the S + M and I/R + M groups,
especially when compared to their respective controls and GSH-Px/GR activities in rats from the
I/R + M groups and I/R rat group. In fact, the only enzyme whose activity somewhat accompanied
changes in the Nrf2 expression was CAT. Its activity was reduced in the I/R group and unchanged in the
I/R + M group. A possible explanation may be that the total Nrf2 transcriptional activity depends not
only on its expression but also on availability of binding partners, the competition and/or cooperation
with other activators and repressors, and crosstalk with other signaling pathways [42]. Moreover, a
meldonium-induced increase in MnSOD activity assumes a more effective removal of superoxide anion
radicals from the site of their most massive production, i.e., the mitochondrial respiratory chain. In this
way, the propagation of oxidative stress from mitochondria to cytoplasm is prevented, which explains
the decreased CuZnSOD activity in rat kidneys from the S + M and I/R + M groups, as well as the
reduced GSH-Px/GR activity in animals from the I/R + M group. Actually, evidence that meldonium
prevents I/R-induced oxidative stress are found from the changes in the concentration of thiol groups
and in the level of lipid peroxidation (Table 2). The concentration of SH groups represents a degree
of the cell reduced state, which is why its increase indicates reduced oxidative stress [43]. The level
of lipid peroxidation, on the other hand, can be considered as a general indicator of oxidative stress.
Our results showed that I/R decreases the SH group’s concentration and increases the level of lipid
peroxidation, while concurrent meldonium pre-treatment decreases the level of lipid peroxidation in
the I/R + M group in comparison to the I/R group, and increases the SH group concentration in both
the S + M and I/R + M groups, especially when compared to their respective control.
We also investigated the ratio between ascorbic acid (the reduced form of vitamin C) and its
oxidized form (dehydroascorbic acid). The AA redox reactions begin with a single-electron oxidation
that generates a mono-dehydroascorbate radical (MDHA), which further dismutates DHA plus AA [16].
Both MDHA and DHA are reduced to ascorbate by several enzymatic systems in a process referred
to as vitamin C recycling [44]. In this way, the AA/DHA ratio can be considered as an important
element in evaluation of tissue antioxidative defense. Other than the kidney, the AA/DHA ratio was
examined in several other tissues. The liver was selected because it is the site of vitamin C synthesis
in rats [45]. Blood was selected because it is the major body depot of vitamin C and is a general
marker of homeostasis. Adrenal glands were selected because of the exceptionally high content of
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vitamin C released into blood in a stressor-specific manner [46]. Moreover, adrenals are the site of
catecholamine synthesis, in which vitamin C serves as a reducing equivalent [17] with the function to
act as a cofactor of dopamine beta-hydroxylase during noradrenaline synthesis [47] and to keep easily
oxidized catecholamines in a reduced state [18]. Since changes in the adrenal AA/DHA ratio may affect
adrenal catecholamines content, we also measured NA and AD concentrations in adrenal glands.
As can be seen in Table 3, all examined tissues showed the same pattern of changes, while I/R
decreased the AA/DHA ratio for 30–40%. Meldonium, alone or in combination with I/R, increased
it. In the case of the I/R + M group, AA/DHA ratio values either return to or surpass the sham level.
A decreased AA/DHA ratio represents a shift in the total vitamin C balance from the reduced into
an oxidized form that indicates attenuation of tissue antioxidant defense and increased oxidative
stress. Conversely, an increase in AA/DHA ratio indicates improved tissue antioxidant defense and
thus a decrease in oxidative stress. These results confirm meldonium’s obvious yet unspecific tissue
antioxidant action. This is in contrast to a previously described kidney-specific antioxidant action
(Table 2, Figure 2).
Table 3. The ascorbic/dehydroascorbic acid ratio (AA/DHA, % of sham) in serum, liver, adrenal gland,
and kidney, as well as adrenal noradrenaline (NA) and adrenaline (AD) content (µg/mg tissue). Group
categories abbreviations: S—sham operated rat group; S + M—sham operated + meldonium rat group;
I/R—ischemia/reperfusion rat group; I/R + M—ischemia/reperfusion + meldonium rat group. Number
of animals per experimental group: n = 8. The data are given as mean ± standard error. Minimal
significant level: p < 0.05. Significantly different: a in respect to S; b in respect to S + M; c in respect to
I/R group.
Experiment Groups S S + M I/R I/R + M
Kidney AA/DHA 100.00 ± 8.76 134.93 ± 7.48 a 64.97 ± 6.77 ab 138.73 ± 7.83 ac
Liver AA/DHA 100.00 ± 8.57 181.28 ± 12.15 a 71.51 ± 6.64 ab 124.60 ± 10.12 bc
Serum AA/DHA 100.00 ± 4.44 197.26 ± 17.02 a 59.99 ± 3.37 ab 91.81 ± 7.25 bc
Adrenal AA/DHA 100.00 ± 5.60 309.07 ± 12.97 a 69.12 ± 4.83 ab 221.09 ± 12.95 abc
Adrenal NA 0.340 ± 0.011 2.185 ± 0.105 a 0.155 ± 0.01 ab 0.462 ± 0.029 abc
Adrenal AD 1.244 ± 0.228 1.068 ± 0.147 1.485 ± 0.346 1.115 ± 0.238
However, it still remains uncertain how renal I/R, which we causes kidney oxidative stress (Table 2,
Figure 2), may cause adverse changes to the AA/DHA ratio in distant organs (i.e., liver and adrenal
glands) (Table 3). It is known that liver represents the major organ that can be remotely damaged by
the renal I/R [48]. The renal I/R causes a release of the numerous inflammatory cytokines, activated
leukocytes, and other neuro-humoral factors that ultimately affect the liver [49]. However, to the best
of our knowledge, there is no literature on the similar effect of renal I/R on adrenal glands.
It is an interesting finding that I/R and meldonium only impact NA content in adrenal glands
without changes in adrenaline content (Table 3). While I/R decreased rat adrenal NA content,
meldonium increased it in rats from both S + M and I/R + M groups. Adrenal glands are known
to have the ability to preferentially synthetize and secrete NA or AD. For example, insulin-induced
hypoglycemia increases adrenaline secretion in cats, while hemorrhage or hypothermia preferentially
increases that of noradrenaline [50]. The biological significance of this phenomenon is related to the
different effects of NA and AD on target tissues, relative to different receptor subpopulations [51].
However, the biological significance in the adrenal content of catecholamines in the case of I/R and
meldonium remains unclear.
Renal necrosis occurs secondary to ischemia [52]. Cellular mechanisms include the rapid loss
of cytoskeletal integrity, the shedding of the proximal tubule brush, the cast formation from cells,
debris detached from the basement membrane, and the leaking of glomerular filtrate from the tubular
lumen to interstitium [53,54]. Our results showed no significant differences in histology between
two sham operated groups (with or without meldonium pre-treatment) (Figure 3A,B). I/R produced
severe tubular necrosis with dilatation of the tubular structure (Figure 3C), cast formation (Figure 3D),
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dilatation of tubular lumina, reduction or loss of brush border, and loss of a cells in some areas
(Figure 3E). However, meldonium pre-treatment reduced histological evidence of renal I/R necrotic
and apoptotic injury, especially regarding tubular structures (Figure 3F).
Lipids are fundamental components of biologic membranes. Depending on the chemical
structure and biosynthesis, lipids can be divided into eight categories: fatty acids (FA), glycerolipids,
sphingolipids, phospholipids, saccharolipids, sterol lipids, prenol lipids, and polyketides [55]. One of
the most important lipid classes is fatty acids. With saturated or unsaturated straight-carbon
chains—with lengths of 4–24 carbon atoms and 0–6 double bonds—fatty acids are a basic component
of all lipids. Glycerolipids are composed of mono-, di-, and tri-esterified glycerols, which all differ in
fatty acid content [56]. Many studies have shown that altered triglyceride synthesis and catabolism
play important roles in the occurrence and development of numerous diseases [57].
To find whether meldonium alone or in combination with I/R will change the FA
renal profile, we investigated the concentration of 13 fatty acids: myristic (tetradecanoic,
C14:0), pentadecylic (pentadecanoic, C15:0), palmitic (hexadecenoic, C16:0), palmitoleic (cis-∆9
hexadecenoic, C16:1), margaric (heptadecanoic, C17:0), stearic (octadecanoic, C18:0), oleic/elaidic
(cis and trans ∆9-octadecenoic, C18:1 c + t), linoleic/linolelaidic (cis and trans ∆9,12-octadecenoic,
C18:2 c + t), behenic (docosanoic, C22:0), cervonic (cis,cis-∆13,16-docosadienoic, C22:6),
and euric (cis,cis,cis,cis,cis,cis-∆4,7,10,13,16,19-docosahexaenoic, C22:1). Under applied chromatographic
conditions, cervonic and euric acids coelute at the same retention time, so their concentrations were
calculated as the sum. The same was the case for cis- and trans- forms of C18:1 and C18:2, so the results
were presented as the 10 fatty acids analysis (Table 4).
Table 4. Kidney fatty acid concentration (µg/g tissue). Group categories abbreviations: S—sham
operated rat group; S + M—sham operated + meldonium rat group; I/R—ischemia/reperfusion rat
group; I/R + M—ischemia/reperfusion + meldonium rat group. Number of animals per experimental
group: n = 8. The data are given as mean ± standard error. Minimal significant level: p < 0.05.
Significantly different: a in respect to S; b in respect to S + M; c in respect to I/R group.
Experiment Groups S S + M I/R I/R + M
C14:0 16.33 ± 2.67 42.00 ± 11.66 a 6.10 ± 1.55 ab 23.50 ± 6.09 bc
C15:0 0.11 ± 0.02 1.29 ± 0.36 a 85.08 ± 21.56 ab 7.23 ± 1.87 abc
C16:0 138.75 ± 22.66 460.83 ± 127.95 a 39.06 ± 9.90 ab 668.69 ± 173.36 ac
C16:1 0.09 ± 0.02 14.38 ± 3.99 a 58.96 ± 12.12 ab 5.18 ± 1.34 abc
C17:0 0.09 ± 0.02 0.34 ± 0.0 a 60.45 ± 14.94 ab 35.66 ± 9.24 ab
C18:0 47.32 ± 7.73 148.22 ± 41.15 a 46.34 ± 15.32 b 251.69 ± 65.25 ac
C18:1 c + t 0.23 ± 0.04 78.19 ± 21.71 a 17.99 ± 11.74 ab 160.71 ± 41.67 ac
C18:2 c + t 18.78 ± 3.07 53.77 ± 14.93 a 25.70 ± 4.56 ab 140.53 ± 36.43 abc
C22:0 0.46 ± 0.07 0.51 ± 0.14 47.85 ± 12.12 ab 0.04 ± 0.01 abc
C22:6 + C22:1 0.80 ± 0.13 1.11 ± 0.31 118.57 ± 30.04 ab 0.11 ± 0.01 abc
Our results showed that I/R, in most cases, caused an increase in FA concentration (C15:0, C16:1,
C17:0, C18:1 c + t, C18:2 c + t, C22:0, and C22:6 + C22:1), with a decrease only in the case of C14:0
and C16:0, and no changes in the case of C18:0. Interestingly, changes caused by meldonium depend
both on treatment and/or FA type. For example, in sham operated animals, meldonium generally
increased concentration of almost all tested fatty acids, with the exception of C22:0 and C22:6 + C22:1,
whose concentrations were not changed. However, in animals subjected to I/R, meldonium in some
cases caused changes that corresponded to those in the S + M group, such as the concentration increase
of C14:0, C16:0, C18:0, C18:1 c + t, and C18:2 c + t. This was not the case with C15:0, C16:1, and C17:0,
whose concentrations meldonium decreased in the I/R + M group, which was in contrast to the increase
it caused in S + M group. Similarly, in I/R animals meldonium caused a C22:0 and C22:6 + C22:1
concentration decrease, which was in contrast to sham operated animals where no chances were caused.
To explore potential similarities and differences between fatty acid profiles across all experimental
groups the principal component analysis was applied (Figure 4). The data were organized in the 4 × 10
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matrix, where rows represent four experimental groups and columns represent 10 fatty acids (alone
or as the sum). The number of significant components (PCs) of this data set was determined by the
percentage of modeled variance. The PCA model with three significant PCs was able to describe
99.85% of the data variance.
Figure 4. The score and the loading plots of kidney fatty acids principle component analysis. Group
categories abbreviations: S—sham operated rat group; S + M—sham operated + meldonium rat group;
I/R—ischemia/reperfusion rat group; I/R + M—ischemia/reperfusion + meldonium rat group. Number
of animals per experimental group: n = 8. The numbers (1–10) on the score plots represent fatty acids:
(1) C14:0; (2) C15:0; (3) C16:0; (4) C16:1; (5) C17:0; (6) C18:0; (7) C18:1 c + t; (8) C18:2 c + t; (9) C22:0; and
(10) C22:6 + C22:1.
As can be seen from our results, the sum of C22:6 and C22:1 exhibits the highest positive value,
whereas C16:0 exhibits the highest negative value (Figure 4A, numbers 10 and 3). Combining this data
with the data from Figure 4Bs loading plot, it can be concluded that C16:0 has the highest influence on
the separation of the I/R group relative to the S, S + M, and IR + M groups (Figure 4B). The greatest
differences between C14:0 and C18:1 c + t (Figure 4C, numbers 1 and 7) is that the highest influence on
the separation between the S and S + M groups (Figure 4D) had the C14:0 while the highest separation
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influence between the I/R + M and S + M groups (Figure 4D) had the C18:1 c + t. Finally, the greatest
differences between C18:1 c + t and C22:6 relative to rests of fatty acids (Figure 4E, numbers 7 and
10) confirmed that the highest influence on the separation of the I/R group relative to the S, S + M,
and IR + M groups (Figure 4F) had the C22:6, while the highest influence on separation between the
I/R + M and S + M groups (Figure 4F) had the C18:1 c + t.
The small- and medium-chain-fatty acids are supposed to be able to enter the mitochondria by
diffusion, whereas long chain fatty acids (C14–C20) require a transport system [58]. In mitochondria,
this purpose serves carnitine palmitoyltransferase-1, the enzyme that meldonium inhibits, causing a
reduction in long-chain fatty acids transporting from cytosol into mitochondria, as well as their
redirection to peroxisomes. In contrast to mitochondria, the peroxisomal fatty acid transport system
is realized by three classed of so-called ABC transporters. ABCD1 has the highest affinity to the
C24:0–C26:0 fatty acids; ABCD2 has the highest affinity to the C22:0–C24:0 and C22:6; and ABCD3 has
the highest affinity to the C20:5 and C16:0 fatty acids [24]. Our results showed that meldonium increases
almost all fatty acids with the exception of C22:0 and C22:6 + C22:1 (Table 4), which suggests that
meldonium restricts mitochondrial use of small and medium-chain-fatty acids, and that the unchanged
concentration of C22:0 and C22:6 + C22:1 belongs to the peroxisomal metabolism. Concerning the
effects of meldonium on I/R, it is known that euric acid (C22:1, number 10 on Figure 4A,C,E) represents
an early sign of renal injury [59]. From this point, a 100-fold increase of C22:1 kidney concentration
can be observed in rats subjected to I/R. This further confirms how extensive renal damage drastically
decreases kidney concentration in animals from the I/R + M group. Alas, this confirms the protective
effect of meldonium (Table 4).
3. Materials and Methods
3.1. Animals and Treatments
All animal procedures were performed in compliance with the ARRIVE guidelines and Directive
2010/63/EU. In accordance with the National legislation, all animal procedures were approved by the
Veterinary Directorate of the Ministry of Agriculture and Forestry and Water Management, License
number 323-07-07137/2018-05 (30.07.2019).
Wistar strain (Rattus norvegicus) male rats weighing 341.63 ± 4.95 g were used for the experiment.
The animals were acclimated to 22 ± 1 ◦C and maintained under a 12 h light/dark period. The rats
were randomly divided into four groups (eight animals per group) and housed two per cage for four
weeks on ad libitum access to a standard diet (Veterinary Institute, Subotica, Serbia) and tap water
(with or without meldonium). In total, we used 32 rats. Rat groups were as follows: animals that
drank tap water for four weeks and then sham operated (S group); animals that drank tap water with
meldonium for four weeks and then sham operated (S + M group); animals that drank tap water for
four weeks and then I/R operated (I/R group); and animals that drank tap water with meldonium for
four weeks and then I/R operated (I/R + M group).
Meldonium (3-(2,2,2-trimetilhidrazinijum) propionate; THP; MET-88) (manufacturer Shenzhen
Calson Bio-Tech Co., Ltd., Shenzhen, China) was dissolved in tap water in concentrations ranging
from 2–3 mg/ml. Depending on the water intake, meldonium concentrations in the water were
adjusted weekly to achieve its consumption of around 300 mg/kg b.m./day. Based on the four-week
measurement, the meldonium consumption was 302.01 ± 4.44 mg/kg b.m./day in sham operated
animals and 301.42 ± 3.67 mg/kg b.m./day in I/R operated animals.
Body mass, body mass gain, and food and water intake were measured weekly throughout the
experiment. The results were expressed as a time course of measured values and recalculated into the
area under a curve (AUC) values.
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3.2. Operative Procedures
Anesthetized rats were subjected to a non-recovery surgical procedure described elsewhere [9].
In brief, sodium thiopental (120 mg/kg, i.p.) was used for the induction of anesthesia. Animals were
placed on their backs on a heating pad to provide constant body temperature of 37.5 ± 1 ◦C. The trachea,
carotid artery, and jugular vein were separated from surrounding tissues and cannulated. The saline
infusion was provided during the whole experiment (8 mL/kg/h before reperfusion, and 2 mL/kg/h
during reperfusion) and anesthesia was maintained by sodium thiopental (10 mg/kg, i.v.). Rats were
subsequently divided into two equal groups: one half was subjected to renal ischemia-reperfusion
injury (I/R operated rats) while another half was followed up without any additional surgical procedure
(sham operated rats).
Ischemia was produced using a reversible clamp that held both renal pedicles with the appropriate
arterial clip for 45 min. At the beginning of reperfusion, clips were removed with big forceps and
kidneys were subjected to reperfusion lasting for four hours. At the end of four-hour reperfusion,
rats were euthanized using an overdose of thiopental sodium.
3.3. Sample Preparation
Blood and tissue samples were collected for further analysis immediately after euthanasia.
Blood was taken into the heparin-coated Eppendorf tubes directly from the intravenous catheter
and inserted into the jugular vein, then incubated at room temperature for 45 min to allow clot
formation. Clots were removed via centrifugation at 2000× g for 10 min in a refrigerated centrifuge.
The resulting supernatant was immediately transferred into a clean polypropylene tube using a Pasteur
pipette [60].
The liver, kidneys, and the adrenals of the rats were isolated and dissected out within 3 min,
then placed in ice-cold 155 mmol NaCl and washed with the same solution. One part of the kidney
was placed in formaldehyde for further histological analysis. The serum and the tissue samples for the
rest of the analysis were stored at −80 ◦C until the analysis.
3.4. Biochemical Analysis
3.4.1. Tissue Preparation
Tissue sample (50 mg) was mixed with 2 mL of ultra-pure water and pulverized with a tissue
grinder. After extraction in an ultrasound bath at 0 ◦C, samples were centrifuged at 12,000 rpm.
The supernatant was transferred in 10 mL normal flask and diluted with ultra-pure water to the mark.
The sample solutions were kept at −80 ◦C till analysis.
3.4.2. Tissue Lactic Acid Determination
The standard of lactic acid was purchased from Sigma Aldrich. Ion chromatography was used
to assay the appearance and quantification of lactic acid. For this purpose, a Dionex ICS-3000
chromatographic setup was used, which consisted of a single pump, a conductivity detector (ASRS
ULTRA II (4 mm) (P/N 061561), recycle mode), a eluent generator (potassium hydroxide (KOH) (P/N
058900)), and a Chromeleon® Chromatography Workstation with Chromeleon 6.7.2 Chromatography
Management software. The separation was performed on IonPac AS15 Analytical, 4 × 250 mm (P/N
053940) and IonPac AG15 Guard, 4 × 50 mm (P/N 053942) column. The mobile phase flow rate was
set to 1000 ml/min, while the concentration of potassium hydroxide was changeable to achieve the
following gradients: 0–15 min 10 mM KOH; 15–25 min 10–45 mM KOH; 25–26 min 45 mM KOH;
26–31 min 45–10 mM KOH; and 31–36 min 10 mM KOH. The column temperature was termostated
at 30 ◦C. The conductivity cell temperature was 35 ◦C. The suppressor current was 134 mA. The
backpressure was ~2200 psi.
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3.4.3. Tissue Glucose Determination
The standard glucose was purchased from Tokyo Chemical Industry, TCI, (Europe, Belgium).
Sodium hydroxide and sodium acetate trihydrate were obtained from Merck (Darmstadt, Germany).
All aqueous solutions were prepared using Ultrapure TKA deionized water. The standard solution
of glucose was prepared in ultrapure water at 100 ng/mL concentration. Calibration standards
were prepared from stock solution by dilution with ultrapure water. The quality control mixture
used for monitoring instrument performance was prepared by diluting concentrations of 20 ng/mL.
Chromatographic separations were performed using DIONEX ICS 3000 DP liquid chromatography
system (Dionex, Sunnyvale, CA, USA) equipped with a quaternary gradient pump (Dionex, Sunnyvale,
CA, USA) and a Carbo Pac®PA100 pellicular anion-exchange column (4 × 250 mm) (Dionex, Sunnyvale,
CA, USA) at 30 ◦C. The mobile phase consisted of the following linear gradients (flow rate, 0.7 mL/min):
0–5 min, 15% A, 85% C; 5.0–5.1 min, 15% A, 2% B 83% C; 5.1–12 min, 15% A 2% B 83% C; 12–12.1 min,
15% A, 4% B, 81% C; 12.1–20 min 15% A, 4% B, 81% C; 20–20.1 min 20% A, 20% B 60% C; 20.1–30 min
20% A, 20% B 60% C; where A was 600 mM sodium hydroxide, B was 600 mM sodium acetate, and C
was ultrapure water. Previously, the analysis system was preconditioned at 15% A and 85% C for
15 min. Each sample (25 µL) was injected with an ICS AS-DV 50 auto sampler (Dionex, Sunnyvale, CA,
USA). The electrochemical detector consisted of gold as working and Ag/AgCl as reference electrode.
3.4.4. Tissue Carnitine Determination
L-Carnitine was obtained from Sigma Aldrich. L-Carnitine (10 mg) was weighted in 10 mL
of a normal flask diluted with ultra-pure water. Next, an ascending thin-layer chromatography
was performed as an adsorbent on RP-18 silica (Art. 5559, Merck, Germany). The chromatograms
were developed using an acetonitrile-water binary mixture with a ratio of 1/1 (v/v). A classical
chromatographic chamber (Camag, Switzerland) was filled with 3 mL of mobile phase made by
components of analytical grade of purity. The chamber was saturated with solvent for 30 min.
All experiments were performed on ambient temperature. The plates were applied with CAMAG
Linomat 5 with 2 µL aliquots of previous prepared and defrosted aqueous solutions. The plates were
scanned using CAMAG TLC Scanner 3 at 260 nm. Chromatograms were analyzed using winCATS
software version 1.4.2.8121.
3.4.5. Tissue Fatty Acid Determination
The fatty acid analysis in the obtained samples was performed using Focus GC and a PolarisQ
mass spectrometer (Thermo Fisher, Waltham, MA, USA). The carrier gas used in this experiment was
helium (1 mL/min) and the injected volume of the sample was 1 µL. The initial temperature for the
oven was 50 ◦C (1 min), then 25 ◦C/min to 200 ◦C, and immediately put to 3 ◦C/min to 230 ◦C (held for
18 min). The injector was in split mode (50:1) while the temperatures of injector, transfer line, and ion
source were 250, 260, and 260 ◦C, respectively.
3.5. Determination of Oxidative Stress Biomarkers
The kidney samples were minced and homogenized in 10 volumes of 25 mmol/L sucrose.
They contained 10 mmol/L Tris-HCl, had a pH of 7.5 at 1500 rpm, and used a Janke and Kunkel
(Staufen, Germany) IKA-Werk Ultra-Turrax homogenizer at 4 ◦C. Homogenates were centrifuged at
4 ◦C at 100,000× g for 90 min and sonicated for 30 s at 10 kHz on ice (Bandeline Sonopuls HD 2070),
followed by centrifugation in a Beckman ultracentrifuge at 100,000× g for 90 min at 4 ◦C. The obtained
supernatants were used for biochemical analyses.
The activity of antioxidant defense enzymes was measured simultaneously in triplicate for each
sample using a Shimadzu UV-1800 spectrophotometer and a temperature-controlled cuvette holder.
The total SOD activity was measured in the supernatant by using the adrenaline method, which is
based on the SOD capacity to inhibit adrenaline autoxidation to adrenochrome [61]. To determine
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MnSOD activity, an assay was performed after the pre-incubation with 8 mmol/L KCN. CuZnSOD
activity was calculated as a difference between total SOD and MnSOD activities. SOD activity was
expressed as U/g wet mass. CAT activity was determined as suggested by Claiborne [62] and expressed
as µmol H2O2/min/g wet mass. The activity of GSH-Px was measured following the oxidation
of nicotinamide adenine dinucleotide phosphate (NADPH) as a substrate at 340 nm with t-butyl
hydroperoxide [63] and expressed in nmol NADPH/min/g wet mass. The activity of GR was evaluated
as suggested by Glatzle et al. [64] and expressed in nmol NADPH/min/g wet mass. GST activity—toward
1-chloro-2,4-dinitro benzene (CDNB) as a substrate—was assayed according to Habig et al. [65] and
expressed in nmol GSH/min/g wet mass. The GSH content was measured according to Griffith’s
method [66], which was based on the sequential oxidation of GSH by 5,5′-dithiobis 2-nitrobenzoicacid
(DTNB), then reduced by NADPH in the presence of GR. The GSH content was expressed as µmol
GSH/g tissue. The concentration of SH groups was determined using DTNB according to the Ellman
method [67] and expressed as nmol SH/g tissue. Lipid peroxide concentration was measured as
thiobarbituric acid reactive substances (TBARS) in animal tissue. It was then assayed using the method
found in Rehncrona et al. [68], which had thiobarbituric acid (TBA) as a reagent. In this reaction,
the colored complex was formed and the absorbance was spectrophotometrically determined at 532 nm.
Lipid peroxide concentration was expressed as nmol TBARS/g tissue. All chemicals used for the
determination of oxidative stress parameters were SIGMA (St. Louis, MO, USA) products.
3.6. Determination of Vitamin C Concentration
The serum, liver, and adrenal concentration of AA and DHA were measured according to the
method established by Nováková et al. [69]. L-Ascorbic acid, phosphoric acid solution (49–51%),
meta-phosphoric acid (MPA), sodium phosphate monobasic dihydrate, and dithiothreitol (DTT)
were purchased from Sigma-Aldrich. Purified water was obtained via a BlueClearRO600P reverse
osmosis water cleaner system with an integrated BlueSoft07-MB mixed bed salt remover (Euro-Clear
Ltd., Hungary).
A stock standard solution of L-Ascorbic acid (1 mg/mL) was prepared in 10% MPA and kept at
−20 ◦C. Standard solutions were prepared by diluting the stock standard solution in 10% MPA.
The phosphate buffer (160 mM, pH 3.0) was used as the mobile phase. Sodium phosphate
monobasic dihydrate (26 g) was accurately weighed, dissolved in approximately 800 mL of water,
and the pH was adjusted to a value of 3.0 with a phosphoric acid solution (49–51%). The resulting
solution was made up to 1 l with water.
Tissue samples were homogenized in 10% MPA (1 mg:10 µL), using an Ultra-Turrax homogenizer,
and sonicated (3 × 10 s). Plasma samples were added to a 10% MPA (9:1, v:v). All samples were
centrifuged (30 min, 18,000 rpm, 4 ◦C). Supernatants were used for the analysis of native AA
concentration. For the analysis of TVC concentration, 100µL of the above supernatant was treated
with 300 µL DTT solution (2.5 mg/mL in phosphate buffer) for 30 min at 4 ◦C for complete conversion
of DHA to AA. The mixture was then re-acidified with 200 µL of 10% MPA and transferred to the
autosampler unit.
The data were obtained using the same HPLC system as described earlier. The following
chromatographic conditions were obtained after the method optimization. The mobile phase that
consisted of the phosphate buffer (160 mM, pH 3.0) was pumped over 10 min in an isocratic flow of
800 µL/min. The applied potential for electrochemical measurements was 600 mV and the separation
temperature was 25 ◦C. The 20 µL of samples and standard solutions were applied to the system.
The concentration of AA and DHA were expressed as µg/mg tissue and µg/mL serum.
3.7. Determination of Catecholamine Concentration
The concentration of adrenaline (AD) and noradrenaline (NA) in the adrenal glands was
performed according to the method of Stefanovic et al. [70]. Ethylene glycol tetra-acetic acid
(EGTA), 5-hydroxytryptamine (5-HT), DL-Noradrenaline hydrochloride (NA), perchloric acid (70%),
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and magnesium chloride (MgCl2 × 5H2O) were purchased from Sigma-Aldrich. Ammonium formate
was supplied by Fisher Scientific, formic acid (49–51%) by Fluka, and methanol by J.T. Baker. Purified
water was obtained via a BlueClearRO600P reverse osmosis water cleaner system with an integrated
BlueSoft07-MB mixed bed salt remover (Euro-Clear Ltd., Gönyu˝, Hungary).
Stock standard solutions of catecholamines (1 mg/mL) were prepared in methanol and kept at
–20 ◦C. Standard solutions were prepared by diluting the stock standard solution in DEPROT (2%
EGTA; 0.1 N HClO4; 0.2% MgCl2).
The ammonium formate buffer (100 mM, pH 3.6) was used as one of the mobile phase components.
Ammonium formate (6.3 g) was accurately weighed and dissolved in approximately 800 ml of water.
Then, the pH was adjusted to the value of 3.6 with formic acid. The resulting solution was made up to
1 l with water.
Tissue samples were homogenized in DEPROT (1 mg:10 µL) using an Ultra-Turrax homogenizer.
They were then sonicated (3 × 10 s) and centrifuged (30 min, 18,000 rpm, 4 ◦C). Supernatants were
transferred in separate tubes and placed in the HPLC system’s autosampler.
We obtained the data using a Thermo Scientific (Dionex UltiMate 3000) HPLC system that consisted
of a degasser unit, binary pump, autosampler, column compartment, and RS electrochemical detector
equipped with a glassy carbon working electrode. An Acclaim Polar Advantage II, C18 (3 µm) HPLC
column (ThermoScientific, Waltham, MA, USA) was used. Instrument control and data acquisition
were carried out using a Chromeleon7 Chromatography Data System (ThermoScientific).
The following chromatographic conditions were obtained after the method optimization.
The mobile phase that had an ammonium formate buffer (100 mM, pH 3.6) as an A solution and
methanol as a B solution was pumped at a flow rate of 500 µL/min with the following gradient. The run
was started with a mobile phase consisting of 98% A and 2% B solution. Starting from the ninth minute
of the run, the B solution rose to reach 80% in the 13th min. Starting from the 18th min until the end
of the run (25th min), the column was re-equilibrated with the initial mixture of each mobile phase
solution (2% of A and 98% of B solution). The potential for electrochemical measurements was 850 mV;
the separation temperature was 25 ◦C. Next, 40 µL worth of samples and standard solutions were
applied into the system. The concentration of catecholamine was expressed as µg/mg tissue.
3.8. Kidney Homogenate Preparation
To prepare for the kidney homogenate, tissue was homogenized in an ice-cold homogenization
buffer (250 mM sucrose, 10 mM Tris-HCl, pH 7.6, 1 mM EDTA), which was supplemented with 1×
phosphatase inhibitor Mix I and 1× protease inhibitor Mix G (Serva). After sonication, the homogenate
was centrifuged at 100 000× g in a Beckmann rotor Ti 50 (Beckman Coulter Inc., Brea, CA 92821, USA)
for 90 min. The resulting supernatant was aliquoted, snap-frozen in liquid nitrogen, and stored at
−80 ◦C.
3.9. Western Immunoblot Analysis
Protein samples of serum (1 µL) or kidney homogenates (50 µg) were separated by 12% SDS-PAGE
and transferred onto polyvinylidene difluoride (PVDF) membranes (Hybond-P, Amersham Pharmacia
Biotech, Little Chalfont, United Kingdom). These samples were then blocked in a solution (0.2% Tween
20, 50 mM TrisHCl pH 7.6, 150 mM NaCl) containing 5% non-fat condensed milk. After the protein
transfer, PVDF membranes were incubated with a primary antibody for 1.5 h at room temperature.
Western immunoblot analysis was performed using Abcam rabbit polyclonal HMGB1 (ab 18256),
Nrf2 (ab 92946), HO-1 (ab 13243), β actin (ab 8227), Bax (2772S), Bcl-2 (2876S) antibodies, Santa Cruz
Biotechnology rabbit polyclonal MnSOD/SOD-2 (sc 30080), p38 (sc 535), p-p38 (sc 7975-R), Akt 1/2/3
(H-136), pAkt1/2/3 (ser 473)-R antibodies, and a goat polyclonal anti-HMGB1 antibody for serum
analysis (K12). The blots were probed with horseradish peroxidase-conjugated secondary Santa Cruz
Biotechnology bovine anti-rabbit IgG pr (sc 2379), bovine anti-goat IgG (sc 2378), and Abcam goat
anti-rabbit IgG (ab 97051) antibodies. Immunoreactive bands were identified using an enhanced
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chemiluminescence (ECL) detection system (Santa Cruz Biotechnology, Santa Cruz, CA, USA) according
to the manufacturer′s instructions. The blots were scanned and the intensities of the signals were
quantified using TotalLab (Phoretix, Newcastle Upon Tyne, UK) electrophoresis software (ver.1.10).
Actin was used as a loading control for the quantification. For re-probing, membranes were incubated
in 2% SDS, 100 mM β-mercaptoethanol, and 62.5 mM Tris-HCl pH 6.8 for 35 min at 50 ◦C, then rinsed
three times, blocked, and probed again with another antibody. All immunoblot analyses were obtained
from at least three independent experiments.
3.10. Histology Analysis
Kidney samples were collected and fixated in 4% formaldehyde solution. After fixation, the samples
were dehydrated in a series of increasing ethanol solutions (70%, 96%, and 100%, respectively) followed
by an immersion in a clearing agent (xylene). The tissue samples were embedded into paraffin wax
and cut into 5 µm thick sections. A minimum of 10 fields for each kidney slide were examined using a
Leica DM LS 2 type 11020518016 microscope (Leica, Wentzler, Germany). The histological analysis
evaluated tubular necrosis, interstitial oedema, loss of brush border, and casts formation.
3.11. Statistical Analysis
Where appropriate, the results were expressed graphically as time-course curves, which were
subsequently recalculated into area under a curve (AUC) values. The single time-point measurements
were presented as mean ± standard errors of mean. AUC values were presented as the percentage of
controls. Data were checked for normality using Lilliefors and Kolmogorov–Smirnov tests. Differences
in investigated parameters between groups were calculated using one-way ANOVA. When significant
differences were found, pairwise comparisons were performed using Holm-Sidak post hoc tests.
The statistical package SIGMAPLOT was used for all the analyses and graphical presentations,
except for the principal component analysis (PCA), which was performed using the NCSS 2004
software package. The level of statistical significance was defined as p < 0.05.
4. Conclusions
Table 5 summarizes the main effects of meldonium and I/R in our experiment. According to the
presented results, it can be concluded that meldonium protects the kidney against I/R-induced injury
in many ways. This includes both anti-apoptotic and anti-necrotic effects, as well as anti-inflammatory
and antioxidative ones. In the case of vitamin C, the antioxidative effect of meldonium does not
appear to be limited to the kidney, but instead extends to the surrounding organs. We also proved
that meldonium increases adrenal concentration of noradrenaline, but this does not yet have an
adequate explanation. Still, this result represents an original contribution to the study of the effects of
meldonium, just like the results suggesting that meldonium has the ability to act as an anti-obesity
agent. Our results of kidney lipidomics are also a novelty in the meldonium study area. Given that the
literature in this field is very scarce, we will direct our future experiments toward clarifying the link
between the meldonium and its effects on lipidomics.
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Table 5. Summarized effects of meldonium and I/R on the kidney carnitine, glucose, and lactic acid
concentration; the protein expression levels of serum HMGB1 and kidney MnSOD; Bax, Bcl-2, HMGB1,
Nrf2, HO-1, and total and phosphorylated p38/Akt; the kidney activities of copper-zinc superoxide
dismutase (CuZnSOD), manganese superoxide dismutase (MnSOD), catalase (CAT), glutathione
peroxidase (GSH-Px), glutathione reductase (GR), and glutathione S-transferase (GST); the kidney
concentrations of sulfhydryl groups (SH) and lipid peroxides (TBARS); the serum, liver, adrenal
gland, and kidney ascorbic/dehydroascorbic acid ratio (AA/DHA); the adrenal noradrenaline (NA) and
adrenaline (AD) content; and the kidney fatty acids concentration. Group categories abbreviations:
S—sham operated rat group; S + M—sham operated + meldonium rat group; I/R—ischemia/reperfusion
rat group; I/R + M—ischemia/reperfusion + meldonium rat group. Up arrow — an increase; Down
arrow—a decrease.
Experiment Groups S + M vs. S I/R vs. S I/R + M vs. I/R
Carnitine ↓ none ↓
Glucose ↓ none ↓
Lactic acid ↓ ↑ ↓
Bax/Bcl2 ratio none ↑ ↓
Serum HMGB1 none ↑ ↓
Kidney HMGB1 none ↑ ↓
MnSOD expression ↑ ↓ ↑
pp38/p38 ratio ↑ ↓ ↑
pAkt/Akt ratio ↑ ↓ ↑
Nrf2 none ↓ ↑
HO1 ↑ ↓ ↑
MnSOD ↑ ↓ ↑
CuZnSOD ↓ none ↓
CAT none ↓ none
GSH-Px none none ↓
GR none none ↓
GST none none none
SH ↑ ↓ ↑
TBARS none ↑ ↓
Kidney AA/DHA ↑ ↓ ↑
Liver AA/DHA ↑ ↓ ↑
Serum AA/DHA ↑ ↓ ↑
Adrenal AA/DHA ↑ ↓ ↑
Adrenal NA ↑ ↓ ↑
Adrenal AD none none none
C14:0 ↑ ↓ ↑
C15:0 ↑ ↑ ↓
C16:0 ↑ ↓ ↑
C16:1 ↑ ↑ ↓
C17:0 ↑ ↑ ↓
C18:0 ↑ none ↑
C18:1 c + t ↑ ↑ ↑
C18:2 c + t ↑ ↑ ↑
C22:0 none ↑ ↓
C22:6 + C22:1 none ↑ ↓
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